Antifungal Coverage in ACLF: Empiric Therapy for High-Risk Patients
In patients with ACLF who have high-risk features (ICU admission, prolonged broad-spectrum antibiotics, central venous catheter, recent abdominal surgery, GI bleeding, or Candida colonization), empiric antifungal therapy should be initiated when there is clinical evidence of sepsis without improvement after 48 hours of appropriate antibacterial therapy, using an echinocandin as first-line treatment. 1, 2
Risk Assessment and Indications for Antifungal Coverage
ACLF patients face a 14.7-20.4% incidence of invasive fungal infections (IFI), with fungal infections occurring almost exclusively as nosocomial infections 3, 2. The mortality risk is substantially elevated when fungal infections complicate ACLF 4, 3, 5.
High-Risk Features Requiring Consideration of Antifungal Coverage:
- Hemodialysis (strongest independent predictor) 3
- Prior antibiotic use (strongest independent predictor) 3
- Diabetes mellitus 3
- Cerebral and respiratory organ failures 3
- Lack of clinical improvement after 48 hours of antibacterial therapy in ICU patients 2
- Recent abdominal surgery, anastomotic leaks, or necrotizing pancreatitis 1
- Multiple Candida colonization sites 6
The AASLD guidance specifically states that in ICU patients with ACLF, lack of clinical improvement after 48 hours should trigger consideration of fungal coverage 2.
Choice of Antifungal Agents
First-Line Empiric Therapy:
Echinocandins are the preferred initial agents for critically ill ACLF patients with suspected invasive candidiasis 1:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
- Micafungin: 100 mg daily
The 2016 IDSA guidelines provide strong recommendations (moderate-quality evidence) that empiric antifungal therapy should be considered in critically ill patients with risk factors for invasive candidiasis, and should be started as soon as possible in patients with septic shock 1.
Alternative Agents:
Fluconazole (800 mg loading dose, then 400 mg daily) can be used in high-risk ICU patients, but this is a weaker recommendation and should be reserved for patients without recent azole exposure and who are not critically ill 1. Given that ACLF patients are by definition critically ill, echinocandins remain preferred.
Lipid formulation amphotericin B (3-5 mg/kg daily) is an alternative when echinocandins cannot be used 1.
Important Caveat:
Do not use azoles in patients with prior azole prophylaxis, as resistance is a concern 7. While short-term fluconazole prophylaxis is unlikely to develop resistance in C. albicans 8, the clinical context of ACLF with multiple risk factors warrants more aggressive initial coverage.
Diagnostic Approach
Biomarkers for Guiding Therapy:
- 1,3-β-D-Glucan (BDG): At cutoff of 80 pg/mL, sensitivity 97.4%, specificity 60%, AUROC 0.770 3
- Galactomannan Index (GMI): At cutoff of 0.5, sensitivity 43.6%, specificity 100%, AUROC 0.745 3
- T2 Candida Panel: Shows promise for earlier detection; earlier antifungal initiation based on T2 Panel results demonstrated mortality benefits (6.15 ± 5.23 days vs 13.53 ± 11.42 days, p ≤ 0.001) 4
BDG and GMI can be useful markers to guide antifungal therapy in patients at high risk for IFI 3. The T2 Candida Panel, when positive, leads to more frequent progression of ACLF and worsening survival outcomes, but earlier treatment based on this test improves mortality 4.
Culture Strategy:
Blood cultures have limited sensitivity (21-71%) for candidemia 4. Follow-up blood cultures should be obtained daily or every other day until they no longer yield yeast 7. Consider sampling from multiple sites including respiratory secretions, urine, and ascitic fluid, though respiratory Candida growth usually indicates colonization rather than infection 1.
Duration of Therapy
Treatment duration should be 2 weeks after documented clearance of Candida from the bloodstream and resolution of signs attributable to candidemia 1. This is a strong recommendation with low-quality evidence.
For intra-abdominal candidiasis, duration should be determined by adequacy of source control and clinical response 1.
Source Control
Source control is mandatory 1:
- Remove all central venous catheters if possible 7, 1
- Provide appropriate drainage and/or debridement for intra-abdominal infections 1
- Address anastomotic leaks or other surgical complications
Common Pitfalls to Avoid
Delaying antifungal therapy: Each hour delay in initiating appropriate therapy increases mortality 2. Start empiric therapy promptly when clinical suspicion is high.
Using fluconazole in critically ill patients: Echinocandins are preferred for moderately severe to severe illness 7.
Ignoring Candida in respiratory secretions: While usually colonization 1, in the context of ACLF with multiple risk factors and clinical deterioration, this may warrant treatment.
Failing to de-escalate: Once culture results return and clinical improvement occurs, de-escalation is important to decrease MDR organism colonization 2.
Inadequate duration: Premature discontinuation can lead to relapse 1. Ensure full 2-week course after clearance.
Prophylaxis Considerations
Prophylactic antifungal therapy is generally not recommended for all ACLF patients. The 2016 IDSA guidelines suggest fluconazole prophylaxis (800 mg loading, then 400 mg daily) could be used in high-risk patients in adult ICUs with institutional invasive candidiasis rates >5%, but this is a weak recommendation 1. Given the specific risk profile of ACLF patients, targeted empiric therapy based on clinical deterioration is preferred over universal prophylaxis.
Epidemiology Specific to ACLF
The most common fungal pathogens are:
- Candida albicans (most common) 5
- Aspergillus fumigatus (second most common, associated with mortality) 8, 5
The most common sources of infection are:
Invasive candidiasis accounts for 64.1% of IFI in ACLF, while invasive aspergillosis accounts for 35.8% 3. This distribution should inform empiric coverage decisions, particularly in patients not responding to echinocandins alone.